Physician profile
Andrew Mangano
NPI 1043402480
$379.37
in general payments reported to CMS, 2019-2025
11 companies · $22.29 in 2025
The $22.29 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.07 · 2022: $55.22 · 2023: $47.09 · 2024: $156 · 2025: $22.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $225.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $117.26 | 2024 | Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.15 | 2022-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $41.92 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $30.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.95 | 2019-2022 | |
| Abbvie INC. | $23.65 | 2023 | |
| Xeris Pharmaceuticals, INC. | $22.29 | 2025 | Gvoke Hypopen |
| Electromed, INC. | $19.81 | 2024 | Smartvest |
| Abbott Laboratories | $18.63 | 2024 | Tendril |
| Alexion Pharmaceuticals, INC. | $17.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mangano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.